Category: Peripheral Stents
Medtronic touts positive 3-year results for the EverFlex self-expanding stent for treating peripheral artery disease it acquired when it bought Covidien for $50 billion.
Healthcare-provider alliance SharedClarity signs some of medtech's biggest firms to land specialized pricing for peripheral stents.
Four of medtech's biggest firms agreed to offer peripheral stents at specialized prices to members of SharedClarity, an organization formed through the alliance of some of the country's largest health insurance and care providers.
Abbott says the FDA granted pre-market approval for its Supera stent for treating peripheral artery disease.
Abbott (NYSE:ABT) said the FDA granted pre-market approval for its Supera peripheral stent.
Abbott Park, Ill.-based Abbott said the stent is designed to conform to the shape of patients' blood vessels. The FDA approved the Supera device for treating occlusions in the superficial femoral artery and the proximal popliteal artery.
Florida-based AxoGen touts an $18 million underwritten public offering of common stock, planning to expand commercial efforts for its peripheral nerve repair products.
Cook Medical launches a clinical study of its Zilver Vena stent, the 1st trial of its kind in the U.S. assessing an iliofemoral venous self-expanding stent.
Indiana medical device giant Cook Medical announced the launch of a new clinical study, the 1st of its kind evaluating the safety and effectiveness of its Zilver Vena venous self-expanding stent.
The VIVO study will enroll select adult patients experiencing limiting leg pain, leg swelling or skin discoloration or a healed or active lower leg ulcer, according to a Cook statement.
Johnson & Johnson's stenting arm, Cordis Corp. furthers its turn away from coronary stents toward the endovascular market with the acquisition of Flexible Stenting Solutions for an undisclosed amount.
Cordis Corp., the stent-making arm of healthcare colossus Johnson & Johnson (NYSE:JNJ), said it's acquired Flexible Stenting Solutions as part of turning its back on the coronary stents market in favor of the endovascular arena.
Medical device company Medtronic wins expanded European regulatory approval for its Complete SE self-expanding vascular stent.
Medtech titan Medtronic (NYSE:MDT) won new European regulatory consideration for its Complete SE vascular stent, gaining approval for use in the arteries that supply blood to the legs.
Medtronic won CE Mark approval in the European Union for use of the Complete SE self-expanding stent in the superficial femoral arteries and proximal popliteal arteries and announced international launch immediately.